Earlier this year, MD Anderson researchers showed that psilocybin could stop chemotherapy from damaging nerves in mice. Now the same team is testing it in actual cancer patients — and the mouse study behind it, published in Science*, reveals a mechanism far more specific than “psilocybin helps somehow.”*
We covered the original finding on this site back when it first came out: psilocybin, given to mice before chemotherapy, appeared to completely prevent peripheral neuropathy — the burning, tingling nerve pain that affects more than a third of chemo patients and can persist for years after treatment ends. At the time, the team behind it, led by Dr. Moran Amit at UT MD Anderson Cancer Center, said human trials were coming within the month. They’ve now arrived: a Phase 2 trial called NeuroGuard, sponsored by MD Anderson, is set to begin enrolling patients this November.
What the mouse study actually found
The underlying research, published in Science in September 2026 with Dr. Amit and pain medicine specialist Dr. Patrick Dougherty as lead investigators, went considerably deeper than the earlier reporting suggested. The mechanism, it turns out, is specific and traceable: chemotherapy drugs like cisplatin damage sensory nerve fibers partly by depleting mitochondria and disrupting their movement along the nerve — starving the fiber’s most distant, energy-hungry tips of the fuel they need to function. Psilocybin, acting through the serotonin 5-HT2A receptor, activates a signaling pathway that keeps those mitochondria moving and properly fueled, protecting the nerve fiber from that energy collapse in the first place.
Two details make the case unusually strong. First, blocking the 5-HT2A pathway directly reversed the protective effect, confirming that’s genuinely the mechanism at work rather than a coincidence. Second — and this is the detail that matters most for how this might eventually be used in the clinic — a non-hallucinogenic compound that activates the same receptor produced the same protection. That raises a real possibility that the therapeutic benefit here doesn’t require the psychedelic experience at all, only the specific receptor signaling behind it. As Dr. Dougherty put it: “Psilocybin does more than reduce pain signals by protecting the nerves, themselves, through energy delivery.”
The preclinical protection held up across multiple chemotherapy drugs — cisplatin, paclitaxel, and docetaxel — with as few as two doses given before treatment preventing cold hypersensitivity, preserving the sensory nerve endings themselves, and maintaining normal touch sensation.
The human trial: NeuroGuard
The Phase 2 trial (NCT07227909) is set to enroll 83 patients with breast, colorectal, or head and neck cancer scheduled for platinum-based chemotherapy or taxanes — the same regimens most strongly linked to neuropathy. Its design is more layered than a simple drug-versus-placebo comparison: one arm receives four full, supervised 25 mg psilocybin doses at specific intervals around the chemotherapy course; a second arm receives a very different regimen entirely — 21 sub-perceptual “microdoses” of just 1 mg over two weeks before chemotherapy begins, testing whether the protective mechanism holds even without a psychedelic dose at all; a third arm receives standard care alone as the comparison group. The trial’s primary outcome, at this stage, is simply safety — tracked through standard NCI adverse-event grading over roughly a year — with the larger question of how well the mechanism translates to actual reduced neuropathy in patients left for the data itself to answer.
Dr. Amit has been candid about both the motivation and the uncertainty here: patients in earlier, unrelated psilocybin trials had anecdotally reported improvements in nerve-related symptoms, which is part of what pushed the team toward formal testing. On moving from mice to actual cancer patients, he was equally direct: “I think that it’s definitely worth a shot,” pointing to the simple fact that no real preventive option for this kind of nerve damage currently exists.
Sources:
- Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models — UT MD Anderson
- ‘Unparalleled’ study finds psilocybin protects against nerve damage from chemotherapy — Scientific American
- NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy — ClinicalTrials.gov (NCT07227909)
